Generic drug freedom-to-operate isn’t about “winning” patents—it’s about designing around them.
If you’ve ever watched a generic launch get delayed by a single, stubborn patent, you already know the uncomfortable truth: the real battleground isn’t the …
Drug patents in Africa: exactly how long they last—and why that timeline matters more than most people think.
Here’s the hook: when a patent expires, it doesn’t just “open the market.” It can change the price of essential medicines, the speed of generi…
Drug Patents in Africa: Exactly How Long They Last Read Post »
Patent vs. Regulatory Exclusivity: The Drug Industry’s Two-Layer Protection System (Explained)
In pharma, “protection” isn’t one thing—it’s two.
And if you’re investing, building a pipeline, negotiating partnerships, or even just trying to understand w…
First-to-File, First-to-Profit: The Real Economics Behind Paragraph IV and 180-Day Exclusivity
In generic drug competition, timing isn’t just strategy—it’s value creation.
A single filing date can determine whether a company captures months of market e…
Pick the right patent—or leave billions on the table.
In pharma, the difference between winning and losing isn’t just the science. It’s the paperwork. The filings. The timing. And—more often than people admit—the choice of which patent you’re actuall…
South America’s drug patent landscape is often treated like a single market—when it’s really a patchwork of rules, timelines, and enforcement realities.
That’s the core takeaway from DrugPatentWatch’s country-by-country breakdown of South American drug…
South American Drug Patents: The Definitive Country-by-Country Breakdown Read Post »
Pharma doesn’t just defend patents anymore—it builds a stack.
In a world where “patent cliffs” are headline events, the more consequential story is happening quietly in the fine print: companies layering exclusivities—NCE (new chemical entity) and orph…
The generic drug race isn’t just about science—it’s about timing, leverage, and a single paragraph.
If you’ve ever wondered why some generic launches feel inevitable while others get delayed for years, the answer is often hiding in plain sight: Hatch-W…
Biopharma’s “Patent Cliff” Isn’t Just a Legal Problem—It’s a Commercial Deadline.
If you’re in biopharma commercial, market access, or vendor services, you already know the story: patents expire, exclusivity fades, and competition arrives faster than m…
Biopharma’s next talent migration isn’t about science—it’s about where the lawsuits are going.
If you want a real-time map of where biopharma careers are headed, don’t start with conferences or job boards. Start with the patent dockets.
A new analysis …
Biosimilar Patent Wars Reveal Exactly Where Biopharma Talent Is Heading Next Read Post »